Navigation Links
Breast Cancer? ER Positive or Negative

A new study reports that recent decline in breast cancer mortality rates have been most noteworthy among women with estrogen receptor (ER)-positive tumors and women younger than 70//.

The results of the study are being published online April 2 in the Journal of Clinical Oncology (JCO).

Approximately 75% of breast cancers are ER-positive. The average age of breast cancer diagnosis is 62.

Between 1990 and 2003, breast cancer mortality rates declined by 24%. This is the first study to examine which patients have experienced the greatest declines in mortality. In 1989, the mortality rate for breast cancer peaked at 33 out of 100,000 women per year. By 2003, the mortality rate had dropped to 25 out of 100,000 women per year.

Although breast cancer mortality has declined for all groups of patients, declines were greatest for women under 70 and women whose tumors were ER-positive. The researchers found that among women under 70, mortality from breast cancer declined 38% for those with ER-positive tumors vs. 19% for those with ER-negative tumors. Among women 70 or older, mortality declined 14% for those with ER-positive tumors vs. no decline for those with ER-negative tumors.

'These trends in breast cancer mortality since 1990 are likely attributable to at least two important factors: the use of tamoxifen after surgery, which substantially reduces the risk of recurrence in ER-positive tumors only; and widespread use of screening mammography, which is more likely to detect the slow-growing tumors that tend to be ER-positive,' said Ismail Jatoi, MD, PhD, Director of the Breast Cancer Center in the Department of Surgery at the National Naval Medical Center, and the study's lead author.

This study did not explore the reasons why breast cancer mortality rates declined less for older women. However, previous studies have suggested that older women are less likely to receive adjuvant therapy for brea st cancer. Because older women are under-represented in clinical trials, their optimal treatment has not been well established.

The researchers point to the importance of further reducing mortality rates among women over 70 and women with ER-negative tumors. The authors argue that recruiting more older women into clinical trials could lead to better treatments and outcomes for this age group. In addition, while a number of breast cancer drugs have recently been introduced that are likely to benefit women with ER-negative tumors, any impact they would have on mortality was not seen during this study period. For example, adjuvant use of Herceptin (trastuzumab) was approved in November 2006 for HER-2+ breast cancer (many ER-negative breast cancers are HER2+).

Investigators at the National Cancer Institute (NCI) and the National Naval Medical Center looked at 234,828 cases of invasive female breast cancer diagnosed between 1990 and 2003. The study analyzed data from the Surveillance Epidemiology and End Results (SEER) cancer registry, an NCI-sponsored, population-based database that compiles detailed cancer statistics.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... CA (PRWEB) , ... May 25, 2016 , ... "FCPX ... the quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... editors can quickly and easily add stylish color grades to their footage. A LUT ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Consumer access ... In early June 2016, Kashi®, a maker of whole grain cereals and other plant-based ... Certified Transitional ingredient: hard red winter wheat processed by Hesco/Dakota Organic Products. , ...
(Date:5/25/2016)... ... , ... Stern Environmental Group , of Secaucus, New Jersey, working in ... Stern’s Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first ... for use in dormitories, shelters, and nursing homes for real time bedbug monitoring in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching ... and patented refillable hanging wipe dispenser. The campaign kick-off video is located via this ... June 25, 2016. The goal is to raise $1,000 per day for a total ...
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the impact ... award to examine gender differences in lung cancer. Today, the Lung Association announced Sharad ... Cancer in Women Award, funded by the American Lung Association’s LUNG FORCE initiative, which ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... May 23, 2016 Experts from ... Precision Medicine and the role of technology in ... The First International Conference of VPS-Penn Medicine opened ... patronage and presence of Sheikh Nahyan bin Mubarak Al Nahyan, ... Precision Medicine, which helps provide personalized medicine and tailor-made healthcare ...
(Date:5/22/2016)... DS Biopharma (DS) today ... compound DS102 in chronic obstructive pulmonary disease (COPD) ... patients. Recent DS preclinical data suggests ... and has bronchodilatory, anti-inflammatory and anti-fibrotic properties in ... will publish further detail on these findings later ...
Breaking Medicine Technology: